Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Development of an anti-claudin-3 and -4 bispecific monoclonal antibody for cancer diagnosis and therapy.

Li X, Iida M, Tada M, Watari A, Kawahigashi Y, Kimura Y, Yamashita T, Ishii-Watabe A, Uno T, Fukasawa M, Kuniyasu H, Yagi K, Kondoh M.

J Pharmacol Exp Ther. 2014 Oct;351(1):206-13. doi: 10.1124/jpet.114.216911.

2.

Pro-chemotherapeutic effects of antibody against extracellular domain of claudin-4 in bladder cancer.

Kuwada M, Chihara Y, Luo Y, Li X, Nishiguchi Y, Fujiwara R, Sasaki T, Fujii K, Ohmori H, Fujimoto K, Kondoh M, Kuniyasu H.

Cancer Lett. 2015 Dec 1;369(1):212-21. doi: 10.1016/j.canlet.2015.08.019.

PMID:
26342407
3.

A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.

Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P, Garcia de Palazzo I.

Cancer Res. 1993 Jan 1;53(1):94-100.

4.

Efficacy and safety evaluation of claudin-4-targeted antitumor therapy using a human and mouse cross-reactive monoclonal antibody.

Hashimoto Y, Kawahigashi Y, Hata T, Li X, Watari A, Tada M, Ishii-Watabe A, Okada Y, Doi T, Fukasawa M, Kuniyasu H, Yagi K, Kondoh M.

Pharmacol Res Perspect. 2016 Sep 27;4(5):e00266.

5.

Generation and characterization of a human-mouse chimeric antibody against the extracellular domain of claudin-1 for cancer therapy using a mouse model.

Hashimoto Y, Tada M, Iida M, Nagase S, Hata T, Watari A, Okada Y, Doi T, Fukasawa M, Yagi K, Kondoh M.

Biochem Biophys Res Commun. 2016 Aug 12;477(1):91-5. doi: 10.1016/j.bbrc.2016.06.025.

PMID:
27286708
6.
7.
8.
9.

Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils.

Tamamori Y, Sawada T, Nishihara T, Yamashita Y, Ohira M, Ho JJ, Kim YS, Hirakawa-Y S Chung K.

Int J Oncol. 2002 Sep;21(3):649-54.

PMID:
12168113
10.

Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas.

Liao SK, Horton L, Flahart RE, O'Rear L, Crumpacker D, Imbaratto JW, Yannelli JR, Robinson RR, Oldham RK.

Hum Antibodies Hybridomas. 1990;1(2):66-76.

PMID:
2103354
11.

Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.

Bruckheimer EM, Fazenbaker CA, Gallagher S, Mulgrew K, Fuhrmann S, Coffman KT, Walsh W, Ready S, Cook K, Damschroder M, Kinch M, Kiener PA, Woods R, Gao C, Dall'Acqua W, Wu H, Coats S.

Neoplasia. 2009 Jun;11(6):509-17, 2 p following 517.

12.

Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity.

Steplewski Z, Sun LK, Shearman CW, Ghrayeb J, Daddona P, Koprowski H.

Proc Natl Acad Sci U S A. 1988 Jul;85(13):4852-6.

13.

Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.

Garcia de Palazzo I, Holmes M, Gercel-Taylor C, Weiner LM.

Cancer Res. 1992 Oct 15;52(20):5713-9.

14.

Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity.

Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, Goto K, Sawa Y, Nishioka Y, Kato Y.

Cancer Sci. 2012 Nov;103(11):1913-9. doi: 10.1111/j.1349-7006.2012.02385.x.

15.

Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers.

Suzuki M, Kato-Nakano M, Kawamoto S, Furuya A, Abe Y, Misaka H, Kimoto N, Nakamura K, Ohta S, Ando H.

Cancer Sci. 2009 Sep;100(9):1623-30. doi: 10.1111/j.1349-7006.2009.01239.x.

16.
17.

Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.

Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A.

Cancer Res. 1999 Mar 15;59(6):1236-43.

18.

Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells.

Rozan C, Cornillon A, Pétiard C, Chartier M, Behar G, Boix C, Kerfelec B, Robert B, Pèlegrin A, Chames P, Teillaud JL, Baty D.

Mol Cancer Ther. 2013 Aug;12(8):1481-91. doi: 10.1158/1535-7163.MCT-12-1012.

19.
20.

Mouse monoclonal antibodies for experimental immunotherapy promotes killing of tumor cells.

Larson LN, Johansson C, Lindholm L, Holmgren J.

Int J Cancer. 1988 Dec 15;42(6):877-82.

PMID:
3192334
Items per page

Supplemental Content

Support Center